These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33080474)

  • 1. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
    Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
    Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
    Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
    Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
    Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
    Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.
    Cajuso T; Hänninen UA; Kondelin J; Gylfe AE; Tanskanen T; Katainen R; Pitkänen E; Ristolainen H; Kaasinen E; Taipale M; Taipale J; Böhm J; Renkonen-Sinisalo L; Mecklin JP; Järvinen H; Tuupanen S; Kilpivaara O; Vahteristo P
    Int J Cancer; 2014 Aug; 135(3):611-23. PubMed ID: 24382590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
    Gu Y; Zhang P; Wang J; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
    Cancer Immunol Immunother; 2023 May; 72(5):1199-1208. PubMed ID: 36369379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
    Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
    J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.
    Niedermaier B; Sak A; Zernickel E; Xu S; Groneberg M; Stuschke M
    Sci Rep; 2019 Dec; 9(1):18207. PubMed ID: 31796878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features.
    Villatoro TM; Ma C; Pai RK
    Hum Pathol; 2020 May; 99():53-61. PubMed ID: 32222462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.
    Salem ME; Battaglin F; Goldberg RM; Puccini A; Shields AF; Arguello D; Korn WM; Marshall JL; Grothey A; Lenz HJ
    Oncologist; 2020 May; 25(5):404-413. PubMed ID: 31848314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of DNA Repair-related Genes as Biomarkers Reflecting MSI, TMB, and TIL in Colorectal Cancer.
    Fukuda J; Sudo T; Kikuchi M; Kawahara A; Shigyo H; Kawamoto Y; Shimamura S; Koga F; Noguchi T; Nakane H; Shigaki T; Fujiyoshi K; Yomoda T; Yoshida N; Koushi K; Yoshida T; Akiba J; Fujita F
    Anticancer Res; 2024 Aug; 44(8):3567-3575. PubMed ID: 39060055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWI/SNF Alterations in Squamous Bladder Cancers.
    Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARID1A mutations in cancer development: mechanism and therapy.
    Zhang X; Zhang Y; Zhao J; Wu Y; Zhang N; Shen W
    Carcinogenesis; 2023 May; 44(3):197-208. PubMed ID: 36882165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
    Harada G; Amano MT; Antonacio FF; Behar MH; Nabuco-de-Araujo PHX; Buchpiguel CA; Junior GC
    Clin Lung Cancer; 2021 Sep; 22(5):e708-e711. PubMed ID: 33658161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.